Figure 6
GB265 and GB266T efficiently suppress tumor growth in PBMC humanized animal model. (a) Schematic of study design. NSG mice were co-engrafted with RKO OKT3 cells and human PBMCs (i.v.). When tumors reached a volume of approximately 100 mm3 (day 0), mice were treated with PBS or indicated antibodies (5 mg/kg, i.v.) and another dose of PBMCs. Antibody treatment was repeated on day 7, and the experiment was terminated on day 14. Tumor volume (b), and animal body weight (c) were monitored during the treatment. Statistical significance on day 14 among treatment groups was assessed using two-way ANOVA with multiple comparisons (Tables S3 and S4). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. ns not significant. Data represent mean ± SD of four mice in each group.
